Head to Head Contrast: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
RegeneRx Biopharmaceuticals (OTCMKTS: RGRX) and Biodel (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
RegeneRx Biopharmaceuticals has a beta of -2.78, meaning that its stock price is 378% less volatile than the S&P 500. Comparatively, Biodel has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
This table compares RegeneRx Biopharmaceuticals and Biodel’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biodel||$11.36 million||18.38||-$4.03 million||N/A||N/A|
RegeneRx Biopharmaceuticals has higher earnings, but lower revenue than Biodel.
Institutional and Insider Ownership
0.2% of RegeneRx Biopharmaceuticals shares are held by institutional investors. Comparatively, 29.2% of Biodel shares are held by institutional investors. 12.1% of RegeneRx Biopharmaceuticals shares are held by company insiders. Comparatively, 22.3% of Biodel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for RegeneRx Biopharmaceuticals and Biodel, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RegeneRx Biopharmaceuticals presently has a consensus target price of $1.50, indicating a potential upside of 710.81%. Biodel has a consensus target price of $61.67, indicating a potential upside of 162.86%. Given RegeneRx Biopharmaceuticals’ higher probable upside, analysts plainly believe RegeneRx Biopharmaceuticals is more favorable than Biodel.
This table compares RegeneRx Biopharmaceuticals and Biodel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Biodel beats RegeneRx Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.